IQWiG: Added Benefit Not Proven For Elocta, But Entresto Sails Through
This article was originally published in Scrip
Executive Summary
Swedish Orphan Biovitrum AB (Sobi) is preparing to respond to an "added benefit not proven" decision on its long-acting recombinant Factor VIII product Elocta (efmoroctocog) from Germany's HTA body, IQWiG, a negative ruling that the company was expecting. The response will be submitted by April 22, just before a scheduled oral meeting with IQWiG in May, with a final decision by the top HTA body, the Federal Joint Committee (G-BA), expected later this year.
You may also be interested in...
Novartis's Entresto Clears NICE But It’s a Close Run Thing
The innovative nature of Novartis's new chronic heart failure therapy Entresto counted towards NICE's appraisal committee clearing its use in Britain's National Health Service, despite a cost-effectiveness ratio that was close to the upper limit for gaining a positive recommendation.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.